Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

Saved in:
Bibliographic Details
Main Authors: NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto
Format: Article
Language:English
Published: PAGEPress Publications 2022-06-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/4990
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846144319238438912
author NICOLA SGHERZA
Stefania Zucano
Angelantonio Vitucci
Antonio Palma
Francesco Tarantini
Daniela Campanale
Luigi Vimercati
Angela Maria Vittoria Larocca
Domenico Visceglie
Amalia Acquafredda
Angelo Ostuni
Daniela Di Gennaro
Carmen Vitucci
Silvio Tafuri
Pellegrino Musto
author_facet NICOLA SGHERZA
Stefania Zucano
Angelantonio Vitucci
Antonio Palma
Francesco Tarantini
Daniela Campanale
Luigi Vimercati
Angela Maria Vittoria Larocca
Domenico Visceglie
Amalia Acquafredda
Angelo Ostuni
Daniela Di Gennaro
Carmen Vitucci
Silvio Tafuri
Pellegrino Musto
author_sort NICOLA SGHERZA
collection DOAJ
format Article
id doaj-art-d24fa06fb0994911b30c7936a8fccfbf
institution Kabale University
issn 2035-3006
language English
publishDate 2022-06-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-d24fa06fb0994911b30c7936a8fccfbf2024-12-02T07:50:38ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062022-06-0114110.4084/MJHID.2022.056Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patientsNICOLA SGHERZA0Stefania ZucanoAngelantonio VitucciAntonio PalmaFrancesco TarantiniDaniela CampanaleLuigi VimercatiAngela Maria Vittoria LaroccaDomenico VisceglieAmalia AcquafreddaAngelo OstuniDaniela Di GennaroCarmen VitucciSilvio TafuriPellegrino Mustoa:1:{s:5:"en_US";s:85:"Unit of Hematology and Stem Cell Transplantation, AOU Consorziale Policlinico di Bari";}https://www.mjhid.org/index.php/mjhid/article/view/4990
spellingShingle NICOLA SGHERZA
Stefania Zucano
Angelantonio Vitucci
Antonio Palma
Francesco Tarantini
Daniela Campanale
Luigi Vimercati
Angela Maria Vittoria Larocca
Domenico Visceglie
Amalia Acquafredda
Angelo Ostuni
Daniela Di Gennaro
Carmen Vitucci
Silvio Tafuri
Pellegrino Musto
Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
Mediterranean Journal of Hematology and Infectious Diseases
title Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
title_full Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
title_fullStr Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
title_full_unstemmed Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
title_short Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients
title_sort prospective case control study of serological response after two doses of bnt162b2 anti sars cov 2 mrna vaccine in transfusion dependent thalassemic patients
url https://www.mjhid.org/index.php/mjhid/article/view/4990
work_keys_str_mv AT nicolasgherza prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT stefaniazucano prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT angelantoniovitucci prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT antoniopalma prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT francescotarantini prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT danielacampanale prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT luigivimercati prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT angelamariavittorialarocca prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT domenicovisceglie prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT amaliaacquafredda prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT angeloostuni prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT danieladigennaro prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT carmenvitucci prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT silviotafuri prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients
AT pellegrinomusto prospectivecasecontrolstudyofserologicalresponseaftertwodosesofbnt162b2antisarscov2mrnavaccineintransfusiondependentthalassemicpatients